Finding bold and innovative solutions to transform patients' lives
CoSolve is a global, virtual, Open Innovation challenge at AstraZeneca, seeking to find new collaborators – those with the boldest innovations and solutions that will help us create the next wave of medicines to help transform patients' lives.
Helping us find real solutions for real challenges we face
At AstraZeneca, we know that however innovative our science, however effective our medicines and delivery, to achieve all we want to achieve, we cannot do it alone.
CoSolve is a quarterly initiative that breaks down the traditional barriers to collaboration and find ideas that are immediately translatable. Each challenge is about helping us accelerate our drug discovery and development to get the right treatments to the right patients.
This means we want bold innovators, particularly from start-ups and early-stage biotechs, with the ability and freedom of operation to rapidly progress their idea into a full project in real time with support from AstraZeneca.
New challenges are announced each quarter and span some of our key therapy areas, and science and technology platforms.
Sign up to our newsletter to hear about future CoSolve challenges.
How does CoSolve work?
CoSolve is all about speed. We are looking for solutions that can be put into practice in a 12-18 month timeframe. Selected partners will be innovators with the ability and freedom of operation to rapidly progress their idea into a full project with support from AstraZeneca. The key steps in the process are:
Challenges which require innovative solutions are posted here in the CoSolve challenge room and will be open for submission for 8 weeks.
Following an in-depth internal review, finalists will be selected to participate in the Challenge Week – a virtual, intensive week where they will pitch a more in-depth proposal of their idea and work up the solution with AstraZeneca scientists.
At the end of the Challenge Week, collaboration agreements will be put in place with specified milestones and the winning projects can begin immediately.
AstraZeneca will provide funding to enable these projects to achieve initial data-driven milestones.